Latest Posts
About This Stock
More About This Stock
Read
Read
Bristol-Myers To Buy Karuna Therapeutics For $14B
Article By:
Zacks Investment Research
Friday, December 22, 2023 11:11 AM EDT
Bristol-Myers Squibb announced that it will acquire the biopharmaceutical company Karuna Therapeutics, Inc. for $330.00 per share in cash for a total equity value of $14 billion in a move to strengthen its neuroscience portfolio.
Premarket Moves: Nike Dips 11%, Karuna Therapeutics Soars 48%
Article By:
The Tokenist
Friday, December 22, 2023 9:11 AM EDT
Friday has seen several stocks make notable moves ahead of the market opening, with Nike (NKE) and Karuna Therapeutics (KRTX) capturing the most attention.